Pfizer Inc v. Micro Labs Ltd

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Pfizer Inc. (Delaware) and PF Prism Imb BV. (Netherlands)
  • Defendant: Micro Labs Limited (India) and Micro Labs USA, Inc. (New Jersey)
  • Plaintiff's Counsel: Morris, Nichols, Arsht & Tunnell LLP
• Case Identification: 1:26-cv-00439, D. Del., 04/16/2026
• Venue Allegations: Venue for the foreign defendant Micro Labs Limited is alleged to be proper in any judicial district. Venue for the domestic defendant Micro Labs USA, Inc. is alleged based on its subjection to personal jurisdiction in the district, prior consent to venue in the district, and a representation by its counsel that it would not object to venue for this action.
• Core Dispute: Plaintiffs allege that Defendants' submission of an Abbreviated New Drug Application (ANDA) to market a generic version of Plaintiffs' CIBINQO (abrocitinib) tablets constitutes an act of patent infringement.
• Technical Context: The technology relates to pyrrolo[2,3-d]pyrimidine derivatives, which function as selective Janus Kinase (JAK) inhibitors for treating immune-mediated diseases like atopic dermatitis.
• Key Procedural History: This action was filed under the Hatch-Waxman Act within 45 days of Plaintiffs' receipt of a notice letter from Defendants. In the letter, Defendants provided a Paragraph IV Certification, asserting that the patents-in-suit are invalid, unenforceable, and/or will not be infringed by the proposed generic product. The complaint notes that Defendants did not contest infringement of the patents in their notice letter. The patents-in-suit are listed in the FDA's "Orange Book" for the CIBINQO product.

Case Timeline

Date	Event
2013-02-22	Priority Date for '074, '405, and '929 Patents
2015-05-19	'074 Patent Issued
2017-01-17	'405 Patent Issued
2017-01-24	'929 Patent Issued
2026-03-04	Defendants' Notice Letter to Plaintiffs
2026-03-27	Email from Defendants' Counsel re: Venue
2026-04-16	Complaint Filed

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 9,035,074 - "Pyrrolo[2,3-D]Pyrimidine Derivatives"

• Patent Identification: 9,035,074, "Pyrrolo[2,3-D]Pyrimidine Derivatives," issued May 19, 2015.

The Invention Explained

• Problem Addressed: The patent addresses the need for new therapeutic compounds that can treat diseases caused by inappropriate protein kinase activity, particularly involving the Janus Kinase (JAK) family of enzymes (JAK1, JAK2, JAK3, and Tyk2) '074 Patent, col. 1:19-38 The background highlights a specific need for compounds that selectively inhibit JAK1 over JAK2 to treat immune disorders while minimizing side effects associated with JAK2 inhibition, such as those related to erythropoietin (EPO) and thrombopoietin (TPO) signaling '074 Patent, col. 1:67-col. 2:10
• The Patented Solution: The patent discloses a class of pyrrolo[2,3-d]pyrimidine derivatives, represented by Formula I, that function as JAK inhibitors '074 Patent, col. 2:11-18 '074 Patent, abstract These compounds are designed to selectively modulate JAK1 activity to treat immune-mediated conditions '074 Patent, col. 2:1-10
• Technical Importance: Developing kinase inhibitors with high selectivity for one family member over another (e.g., JAK1 vs. JAK2) was a significant goal in drug discovery to create safer and more effective treatments for autoimmune diseases.

Key Claims at a Glance

• The complaint alleges infringement of one or more claims of the '074 patent but does not specify which claims will be asserted '074 Patent, col. 37 The patent includes claims to a genus of chemical compounds (e.g., Claim 1), specific compounds (e.g., Claim 10), and pharmaceutical compositions containing them.

U.S. Patent No. 9,545,405 - "Pyrrolo[2,3-D]Pyrimidine Derivatives"

• Patent Identification: 9,545,405, "Pyrrolo[2,3-D]Pyrimidine Derivatives," issued January 17, 2017.

The Invention Explained

• Problem Addressed: Like the parent '074 patent, the '405 patent is directed to the problem of treating immune-mediated disorders caused by dysregulation of the JAK signaling pathway '405 Patent, col. 1:19-col. 2:10 It specifically identifies disorders such as atopic dermatitis, psoriasis, and other allergic reactions as targets for therapy '405 Patent, col. 3:37-44
• The Patented Solution: The '405 patent claims methods of treating specific diseases by administering a therapeutically effective amount of the pyrrolo[2,3-d]pyrimidine compound abrocitinib or a salt thereof '405 Patent, claim 1 The patent focuses on the use of the compound for therapeutic intervention in mammals, including companion animals and humans '405 Patent, col. 3:45-49
• Technical Importance: This patent provides protection not just for the chemical compound itself but for its specific application in treating particular diseases, a critical component of pharmaceutical patent portfolios.

Key Claims at a Glance

• The complaint alleges infringement of one or more claims but does not specify which will be asserted Compl. ¶57 Representative independent claims include methods for treating atopic dermatitis (Claim 1), psoriasis (Claim 7), and allergic dermatitis (Claim 11) by administering the patented compound.

U.S. Patent No. 9,549,929 (Multi-Patent Capsule) - "Pyrrolo[2,3-D]Pyrimidine Derivatives"

• Patent Identification: 9,549,929, "Pyrrolo[2,3-D]Pyrimidine Derivatives," issued January 24, 2017.
• Technology Synopsis: This patent is also in the same family and addresses the need for effective treatments for JAK-mediated disorders. It specifically claims crystalline forms of the active pharmaceutical ingredient abrocitinib, which can provide advantages in stability, manufacturing, and bioavailability over amorphous or other crystalline forms.
• Asserted Claims: The complaint alleges infringement of one or more unspecified claims Compl. ¶77 The patent claims are directed to specific solid-state forms of abrocitinib, such as "crystalline Form A" (Claim 1).
• Accused Features: The infringement allegation targets the active pharmaceutical ingredient within the "Micro Labs ANDA Product" Compl. ¶75

III. The Accused Instrumentality

Product Identification

• The accused instrumentality is the "Micro Labs ANDA Product," which comprises generic abrocitinib tablets in 50 mg, 100 mg, and 200 mg dosage strengths Compl. ¶20

Functionality and Market Context

• The complaint alleges that the Micro Labs ANDA Product is a generic copy of Plaintiffs' CIBINQO® (abrocitinib) tablets Compl. ¶21 CIBINQO® is approved for the treatment of adult and pediatric patients (12 years and older) with refractory, moderate-to-severe atopic dermatitis Compl. ¶18 The accused product is therefore a JAK inhibitor intended for the same therapeutic use. The filing of ANDA No. 221196 signals Defendants' intent to commercially manufacture and sell this generic version in the United States upon FDA approval Compl. ¶20 Compl. ¶24
• No probative visual evidence provided in complaint.

IV. Analysis of Infringement Allegations

The complaint, characteristic of initial filings in ANDA litigation, does not provide a claim-by-claim breakdown of its infringement allegations or reference any preliminary claim charts. The infringement counts are based on the statutory act of infringement created by the submission of ANDA No. 221196 under 35 U.S.C. § 271(e)(2)(A) Compl. ¶35 Compl. ¶55 Compl. ¶75 The complaint alleges that Defendants' notice letter and its accompanying detailed statement did not contest infringement of any of the patents-in-suit Compl. ¶37 Compl. ¶57 Compl. ¶77 Therefore, a detailed claim chart analysis is not possible based on the complaint alone.

• Identified Points of Contention:
  • '074 Patent (Compound): Because the accused product contains the same active pharmaceutical ingredient (abrocitinib) as Plaintiffs' CIBINQO®, and because the complaint alleges Defendants did not contest infringement Compl. ¶37, the primary dispute concerning this patent will almost certainly be over its validity and/or enforceability, which Defendants challenged in their Paragraph IV certification Compl. ¶22
  • '405 Patent (Method of Use): The infringement analysis for this patent will focus on the doctrine of inducement. The central question will be whether the product label submitted with Defendants' ANDA will instruct or encourage physicians and patients to use the generic product in a manner that practices the steps of the asserted method claims (e.g., administering a therapeutically effective amount of abrocitinib to treat atopic dermatitis) Compl. ¶77
  • '929 Patent (Crystalline Form): The dispute for this patent will likely be a highly technical, factual one. The question will be whether the active pharmaceutical ingredient in the "Micro Labs ANDA Product" is the same crystalline form of abrocitinib as that claimed in the '929 patent. This would be determined through analytical techniques such as X-ray powder diffraction (XRPD).

V. Key Claim Terms for Construction

The complaint does not identify specific claims or propose constructions. However, based on the subject matter of the patents, the following terms may become central to the dispute.

• Analysis for '074 Patent: The complaint does not provide sufficient detail for analysis of key claim terms. As infringement is reportedly not contested, claim construction is less likely to be a focus for this patent compared to validity challenges.
• Analysis for '405 Patent:
  • The Term: "therapeutically effective amount" (from Claim 1).
  • Context and Importance: This term is fundamental to any method-of-treatment claim. Its definition is critical for determining what dosage regimens are covered by the patent. Practitioners may focus on this term to argue that the dosages specified in the defendant's proposed label either fall within or outside the scope of a "therapeutically effective amount" as understood in the context of the patent.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: The specification may describe a wide range of potential dosages or define the term functionally as any amount sufficient to produce a desired therapeutic response, such as the alleviation of symptoms '405 Patent, col. 13:11-16 '405 Patent, col. 15:8-14
    • Evidence for a Narrower Interpretation: The specification may provide specific examples of dosage ranges used in clinical studies or preferred embodiments, which could be used to argue for a more limited definition of what constitutes a "therapeutically effective amount" '405 Patent, col. 13:12-20

VI. Other Allegations

• Indirect Infringement: The complaint alleges that upon approval, Defendants will actively induce infringement and contribute to the infringement of all three patents-in-suit Compl. ¶37 Compl. ¶57 Compl. ¶77 For the '405 method-of-use patent, this allegation is specifically supported by the claim that the proposed product labeling will instruct physicians and patients to use the product in an infringing manner Compl. ¶77
• Willful Infringement: Plaintiffs allege that Defendants have acted with "full knowledge" of the patents-in-suit and "without a reasonable basis" for believing they would not be liable, based on their pre-suit receipt of the Paragraph IV notice letter Compl. ¶38 Compl. ¶58 Compl. ¶78 Plaintiffs request a finding that the case is "exceptional" and an award of attorneys' fees, consistent with an allegation of willful or egregious conduct Compl., Prayer for Relief ¶F

VII. Analyst's Conclusion: Key Questions for the Case

• A primary question will be one of validity: Since the complaint alleges that infringement was not contested in the Defendants' notice letter, the case will likely center on whether Defendants can prove by clear and convincing evidence that the asserted claims of the '074, '405, and '929 patents are invalid for reasons such as anticipation or obviousness.
• A secondary question will be one of induced infringement: For the '405 method-of-use patent, a key issue will be whether the language in the final, FDA-approved label for Micro Labs' generic product is sufficient to establish that Defendants intended to cause infringement by physicians and patients.
• A key evidentiary question will be one of factual identity: Regarding the '929 patent, the dispute will turn on a technical comparison of the solid-state chemistry of the parties' products: does the abrocitinib in Micro Labs' ANDA product exhibit the specific crystalline form protected by the '929 patent claims?